Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763008 | 0.86 | CXCR2 (0.67) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6763521 | 0.85 | FADS1 (0.64) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL4351611 | 0.84 | TRPV1 (0.62) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL4112669 | 0.83 | NPC1 (0.81) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL6760901 | 0.83 | EPHX2 (0.56) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6567616 | 0.81 | CXCR2 (0.73) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL4117269 | 0.78 | CNR1 (0.84) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL30469272 | 0.78 | CNR1 (0.84) | MAPTMEN1KMT2AGRIK1CNR1 | |
| SCHEMBL6763526 | 0.77 | MAPT (0.77) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6764064 | 0.77 | P2RX1 (0.64) | MAPTMEN1KMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20040063742-A1 | Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity | NEUROSEARCH A/S (DK) | 2004-04-01 | — | — | US | claimed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| US-20040063742-A1 | Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity | NEUROSEARCH A/S (DK) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | MAPT 4034/4885MEN1 2084/4885KMT2A 2189/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | MAPT 4034/4885MEN1 2084/4885KMT2A 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.